1491 related articles for article (PubMed ID: 33513400)
1. Cardiovascular protective properties of oxytocin against COVID-19.
Wang SC; Wang YF
Life Sci; 2021 Apr; 270():119130. PubMed ID: 33513400
[TBL] [Abstract][Full Text] [Related]
2. Potential of Endogenous Oxytocin in Endocrine Treatment and Prevention of COVID-19.
Wang SC; Zhang F; Zhu H; Yang H; Liu Y; Wang P; Parpura V; Wang YF
Front Endocrinol (Lausanne); 2022; 13():799521. PubMed ID: 35592777
[TBL] [Abstract][Full Text] [Related]
3. Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review.
Aleksova A; Gagno G; Sinagra G; Beltrami AP; Janjusevic M; Ippolito G; Zumla A; Fluca AL; Ferro F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926110
[TBL] [Abstract][Full Text] [Related]
4. Oxytocin, the panacea for long-COVID? a review.
Diep PT; Chaudry M; Dixon A; Chaudry F; Kasabri V
Horm Mol Biol Clin Investig; 2022 Sep; 43(3):363-371. PubMed ID: 35576613
[TBL] [Abstract][Full Text] [Related]
5. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
Ramasamy S; Subbian S
Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
[TBL] [Abstract][Full Text] [Related]
6. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science.
Evans PC; Rainger GE; Mason JC; Guzik TJ; Osto E; Stamataki Z; Neil D; Hoefer IE; Fragiadaki M; Waltenberger J; Weber C; Bochaton-Piallat ML; Bäck M
Cardiovasc Res; 2020 Dec; 116(14):2177-2184. PubMed ID: 32750108
[TBL] [Abstract][Full Text] [Related]
7. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up.
Tajbakhsh A; Gheibi Hayat SM; Taghizadeh H; Akbari A; Inabadi M; Savardashtaki A; Johnston TP; Sahebkar A
Expert Rev Anti Infect Ther; 2021 Mar; 19(3):345-357. PubMed ID: 32921216
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic potential of regulatory T cells in reducing cardiovascular complications in patients with severe COVID-19.
Saghafi N; Rezaee SA; Momtazi-Borojeni AA; Tavasolian F; Sathyapalan T; Abdollahi E; Sahebkar A
Life Sci; 2022 Apr; 294():120392. PubMed ID: 35149115
[TBL] [Abstract][Full Text] [Related]
10. An Assessment on Impact of COVID-19 Infection in a Gender Specific Manner.
Agrawal H; Das N; Nathani S; Saha S; Saini S; Kakar SS; Roy P
Stem Cell Rev Rep; 2021 Feb; 17(1):94-112. PubMed ID: 33029768
[TBL] [Abstract][Full Text] [Related]
11. Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.
Imami AS; O'Donovan SM; Creeden JF; Wu X; Eby H; McCullumsmith CB; Uvnäs-Moberg K; McCullumsmith RE; Andari E
Physiol Genomics; 2020 Sep; 52(9):401-407. PubMed ID: 32809918
[TBL] [Abstract][Full Text] [Related]
12. Oxytocin as a Potential Adjuvant Against COVID-19 Infection.
Thakur P; Shrivastava R; Shrivastava VK
Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1155-1162. PubMed ID: 32914732
[TBL] [Abstract][Full Text] [Related]
13. Tumor Necrosis Factor-Alpha Exacerbates Viral Entry in SARS-CoV2-Infected iPSC-Derived Cardiomyocytes.
Lee CY; Huang CH; Rastegari E; Rengganaten V; Liu PC; Tsai PH; Chin YF; Wu JR; Chiou SH; Teng YC; Lee CW; Liang Y; Chen AY; Hsu SC; Hung YJ; Sun JR; Chien CS; Chien Y
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576032
[TBL] [Abstract][Full Text] [Related]
14. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic application of estrogen for COVID-19: Attenuation of SARS-CoV-2 spike protein and IL-6 stimulated, ACE2-dependent NOX2 activation, ROS production and MCP-1 upregulation in endothelial cells.
Youn JY; Zhang Y; Wu Y; Cannesson M; Cai H
Redox Biol; 2021 Oct; 46():102099. PubMed ID: 34509916
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular aspects of COVID-19.
Kurz DJ; Eberli FR
Swiss Med Wkly; 2020 Dec; 150():w20417. PubMed ID: 33382450
[TBL] [Abstract][Full Text] [Related]
18. Papaverine, a promising therapeutic agent for the treatment of COVID-19 patients with underlying cardiovascular diseases (CVDs).
Valipour M; Irannejad H; Emami S
Drug Dev Res; 2022 Sep; 83(6):1246-1250. PubMed ID: 35706384
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
Hu Y; Liu L; Lu X
Front Endocrinol (Lausanne); 2021; 12():725967. PubMed ID: 34745001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
